Oculus Innovative Sciences Announces Positive Results from Abstract Evaluating the Use of Microcyn(R) Technology in Treatment of Atopic Dermatitis Jul 1, 2008
Oculus Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal Health Co. Ltd. for Development of Microcyn(R) Technology Use in Chinese Animal Market Jun 23, 2008
Oculus Innovative Sciences Announces Agreement with Bayer Australia Limited for Development of Microcyn(R) Technology Use in Australian Animal Market Jun 19, 2008
Oculus Innovative Sciences Announces Development of Microcyn(R)-Based Hydrogel Formulation Jun 17, 2008
Oculus Innovative Sciences Announces Breakthrough Antimicrobial Formulation for Over-The-Counter Non-Wound Market to be Launched in U.S. Without Pre-Approval by the FDA Jun 16, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update Jun 11, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update Release and Conference Call Jun 5, 2008
Oculus Innovative Sciences Files for Patent Protection on Breakthrough Wound Care Device to Accelerate Wound Healing Jun 4, 2008
Oculus Innovative Sciences Announces Market Assessment of Near-Term Commercialization Opportunities in the United States for Dermacyn(TM) Wound Care Jun 2, 2008
Oculus Innovative Sciences Announces Publication of Microcyn(R) Technology Post-Caesarean Section Wound Study in Indian Medical Gazette May 28, 2008
